IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis

摘要

IC100 treatment improves the functional outcome in EAE. Clinical course of MOG -induced EAE in C57BL/6 mice treated with vehicle or increasing doses of IC100 (10, 30, and 45 mg/kg i.p. every 4 days) with administration starting at day 8. Results are expressed as daily mean clinical score ± SEM of 9–10 mice/group. Statistical analysis by 2-way repeated measures ANOVA with Tukey’s multiple comparisons test: The number sign indicates significantly different time point, Vehicle vs IC100 10 mg/kg: value 14 dpi = 0.0313. The asterisk indicates significantly different time points, vehicle vs IC100 30 mg/kg: values 14–18 dpi = 0.0089, 0.0031, 0.0053, 0.0002, 0.0034; values 27–30 dpi = 0.0191, 0.0116, 0.046, 0.04. The caret symbol indicates significantly different time points, vehicle vs IC100 45 mg/kg: values 14–18 dpi = 0.0089, 0.0179, 0.02, 0.0023, 0.0377; values 27–29 dpi = 0.0377, 0.0079, 0.0392. The double asterisk symbol indicates curve comparisons: vehicle vs IC100 30 mg/kg, = 0.0025; vehicle vs IC100 45 mg/kg, = 0.004, Mann-Whitney test. – Comparison of EAE parameters between vehicle-treated mice and each of the two effective doses: , Cumulative Disease Index (CDI), calculated as sum of daily scores from day of onset for each animal (measure of EAE severity), * ≤ 0.05, Mann-Whitney test; , Onset day, considered as day a mouse showed EAE symptoms for two consecutive days; ( , ) Peak clinical score, considered as highest score reached by a mouse acutely after onset, * ≤ 0.05, Student’s test; , Peak disease day, considered as day a mouse reached the highest disease score acutely after onset